ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Cancer Policy; Board Suggests More Detailed Items In Tobacco Agreement

August 22, 1997

PET Better At Evaluating Response In Sarcoma

February 29, 2008

In Brief: Owens New President Of AACI, Yates President Elect; UNC Gains Comprehensive Center Status

June 29, 1990

AACR Meeting: Celebrex Studies Show Benign Polyp Reduction, Point To Challenges In Biomarker Validation.

April 14, 2006

Includes January Business & Regulatory Report (8-page issue).

January 31, 2003

Cancer Leadership Council Letter Calls For Permanent Leadership of NCI and FDA.

November 22, 2006